Vaccinogen

Biotechnology ResearchGeorgia, United States2-10 Employees

Vaccinogen is a US-based biotechnology company formed in 2007 currently commercializing a personalized immunotherapy designed to prevent disease recurrence after cancer surgery (OncoVAX®). Using a patient’s own tumor as the source material for their treatment, this patented approach has proven to prevent advanced stage II colorectal cancer recurrence with 15 years of patient follow-up compared to surveillance alone. While this Phase IIIb study with Fast Track Designation represents the most near-term source of revenue for the company, new sources of funding will also allow Vaccinogen to develop and commercialize the truly unique, cancer-specific antibodies created by OncoVAX patients into the next product portfolio for the company: bispecific T-cell engagers, antibody-drug conjugates, solid tumor CAR-T, and radioligands with broad specificity against a range of adenocarcinomas – each with pipeline in a product potential. See our website for more details on our science and contact information for investment opportunities.

Sign up for free to view info

Email Format Employee directory